Inicio
Información del autor
Autor Luz Natalia Builes Restrepo
Comentario :
Médica Hematóloga Pediatra, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (6)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaHaploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis / Luz Natalia Builes Restrepo ; Andrés Felipe Escobar González
Título : Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, Fecha de publicación : 2021 Títulos uniformes : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis [documento electrónico] / Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, . - 2021.
Obra : Journal of Clinical Immunology
Idioma : Inglés (eng)
Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001687 AC-2021-013 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Hemangioendotelioma kaposiforme refractario en población pediátrica: reporte de caso y revisión de la literatura Otros títulos : Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review Tipo de documento : documento electrónico Autores : Jorge Alberto Ochoa Gaviria, ; Luz Natalia Builes Restrepo, Fecha de publicación : 2021 Títulos uniformes : Boletín Médico del Hospital Infantil de México Idioma : Español (spa) Palabras clave : Hemangioendotelioma kaposiforme Sirolimus Fenómeno de Kasabach-Merritt Resumen : Introducción: El hemangioendotelioma kaposiforme (HEK) es un tumor vascular poco frecuente caracterizado por una invasión local agresiva y un síndrome de atrapamiento de plaquetas conocido como fenómeno de Kasabach-Merritt. Aunque muchos casos de HEK se tratan con éxito con control local o quimioterapia de baja intensidad, otros son resistentes y se cuenta con pocas opciones terapéuticas. El objetivo de este reporte es mostrar la experiencia del tratamiento con sirolimus por vía oral en un paciente pediátrico con HEK asociado a fenómeno de Kasabach-Merritt refractario al tratamiento de primera línea, quien mostró excelente respuesta al tratamiento. Caso clínico: Paciente de sexo masculino de 3 meses con un HEK refractario al manejo de primera línea (corticoides, propranolol, vincristina), sin posibilidad de hacer control local, por lo que se decide terapia combinada con sirolimus, presentando control local y resolución de la coagulopatía desde la primera semana de iniciado el manejo y con resolución de la malformación vascular después de 12 meses de seguimiento. Conclusiones: Aunque no existen pautas claras para el tratamiento del HEK refractario en la edad pediátrica, la evidencia actual demuestra que el sirolimus es un medicamento eficaz que puede ser considerado como opción terapéutica de primera línea en estos pacientes. Mención de responsabilidad : Claudia P. Gómez-Villegas, Camila Pérez-Téllez, Jorge Ochoa-Gaviria y Natalia Builes Referencia : Bol Med Hosp Infant Mex. 2021;78(4):376-384. DOI (Digital Object Identifier) : 10.24875/BMHIM.20000304 PMID : 34351887 Derechos de uso : CC BY-NC-ND En línea : https://www.bmhim.com/frame_esp.php?id=249 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5812 Hemangioendotelioma kaposiforme refractario en población pediátrica: reporte de caso y revisión de la literatura = Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review [documento electrónico] / Jorge Alberto Ochoa Gaviria, ; Luz Natalia Builes Restrepo, . - 2021.
Obra : Boletín Médico del Hospital Infantil de México
Idioma : Español (spa)
Palabras clave : Hemangioendotelioma kaposiforme Sirolimus Fenómeno de Kasabach-Merritt Resumen : Introducción: El hemangioendotelioma kaposiforme (HEK) es un tumor vascular poco frecuente caracterizado por una invasión local agresiva y un síndrome de atrapamiento de plaquetas conocido como fenómeno de Kasabach-Merritt. Aunque muchos casos de HEK se tratan con éxito con control local o quimioterapia de baja intensidad, otros son resistentes y se cuenta con pocas opciones terapéuticas. El objetivo de este reporte es mostrar la experiencia del tratamiento con sirolimus por vía oral en un paciente pediátrico con HEK asociado a fenómeno de Kasabach-Merritt refractario al tratamiento de primera línea, quien mostró excelente respuesta al tratamiento. Caso clínico: Paciente de sexo masculino de 3 meses con un HEK refractario al manejo de primera línea (corticoides, propranolol, vincristina), sin posibilidad de hacer control local, por lo que se decide terapia combinada con sirolimus, presentando control local y resolución de la coagulopatía desde la primera semana de iniciado el manejo y con resolución de la malformación vascular después de 12 meses de seguimiento. Conclusiones: Aunque no existen pautas claras para el tratamiento del HEK refractario en la edad pediátrica, la evidencia actual demuestra que el sirolimus es un medicamento eficaz que puede ser considerado como opción terapéutica de primera línea en estos pacientes. Mención de responsabilidad : Claudia P. Gómez-Villegas, Camila Pérez-Téllez, Jorge Ochoa-Gaviria y Natalia Builes Referencia : Bol Med Hosp Infant Mex. 2021;78(4):376-384. DOI (Digital Object Identifier) : 10.24875/BMHIM.20000304 PMID : 34351887 Derechos de uso : CC BY-NC-ND En línea : https://www.bmhim.com/frame_esp.php?id=249 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5812 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001746 AC-2021-062 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-062Adobe Acrobat PDF
Título : Histiocitosis de células de Langerhans: Reporte de caso y revisión de la literatura Otros títulos : Langerhans cell histiocytosis: Case report and literature review Tipo de documento : documento electrónico Autores : Carolina Echeverri Jaramillo, ; Luz Natalia Builes Restrepo, Fecha de publicación : 2021 Títulos uniformes : Biomédica Idioma : Español (spa) Palabras clave : Histiocitosis de células de Langerhans Histiocytosis Pediatría conjuntivtis aguda celulitis preseptal absceso postseptal dermatitis seborreica Resumen : La histiocitosis de células de Langerhans comprende un grupo heterogéneo de enfermedades inflamatorias para las cuales las células dendríticas y los macrófagos son los principales componentes celulares. El infiltrado inflamatorio puede afectar la piel y otros órganos, y el resultado clínico varía de leve a letal dependiendo del subconjunto de células involucradas y al compromiso multisistémico. La demora en el diagnóstico puede ocurrir debido a su presentación inespecífica y probablemente a una baja sospecha por parte del clínico. Reportamos el caso de una lactante mayor quien a pesar de múltiples consultas con síntomas inespecíficos pero característicos de la enfermedad solo se logró diagnosticar gracias a los hallazgos histopatológicos. Mención de responsabilidad : Miguel Ángel Medina, Wendy Meyer, Carolina Echeverri, Natalia Builes Referencia : Biomedica. 2021 Sep 22;41(3):396-402. DOI (Digital Object Identifier) : 10.7705/biomedica.5430 PMID : 34559487 Derechos de uso : CC BY En línea : https://revistabiomedica.org/index.php/biomedica/article/view/5430 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5766 Histiocitosis de células de Langerhans: Reporte de caso y revisión de la literatura = Langerhans cell histiocytosis: Case report and literature review [documento electrónico] / Carolina Echeverri Jaramillo, ; Luz Natalia Builes Restrepo, . - 2021.
Obra : Biomédica
Idioma : Español (spa)
Palabras clave : Histiocitosis de células de Langerhans Histiocytosis Pediatría conjuntivtis aguda celulitis preseptal absceso postseptal dermatitis seborreica Resumen : La histiocitosis de células de Langerhans comprende un grupo heterogéneo de enfermedades inflamatorias para las cuales las células dendríticas y los macrófagos son los principales componentes celulares. El infiltrado inflamatorio puede afectar la piel y otros órganos, y el resultado clínico varía de leve a letal dependiendo del subconjunto de células involucradas y al compromiso multisistémico. La demora en el diagnóstico puede ocurrir debido a su presentación inespecífica y probablemente a una baja sospecha por parte del clínico. Reportamos el caso de una lactante mayor quien a pesar de múltiples consultas con síntomas inespecíficos pero característicos de la enfermedad solo se logró diagnosticar gracias a los hallazgos histopatológicos. Mención de responsabilidad : Miguel Ángel Medina, Wendy Meyer, Carolina Echeverri, Natalia Builes Referencia : Biomedica. 2021 Sep 22;41(3):396-402. DOI (Digital Object Identifier) : 10.7705/biomedica.5430 PMID : 34559487 Derechos de uso : CC BY En línea : https://revistabiomedica.org/index.php/biomedica/article/view/5430 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5766 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001692 AC-2021-017 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-017Adobe Acrobat PDF
Título : Hematopoietic stem cell transplantation in children with inborn errors of immunity: a multi-center experience in Colombia Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, Fecha de publicación : 2020 Títulos uniformes : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hematopoietic stem cell transplantation child haploidentical transplantations pediatrics primary immunodeficiency diseases transplant recipients Resumen : Purpose: To characterize the pediatric population with inborn errors of immunity (IEI) that was treated with hematopoietic stem cell transplantation (HSCT) in three reference centers in Colombia. What have been the characteristics and outcomes of hematopoietic stem cell transplantation in pediatric patients with inborn errors of immunity in three reference care centers in Colombia between 2007 and 2018. Methods: We conducted an observational, retrospective cohort study in children with a diagnosis of IEI who underwent HSCT between 2007 and 2018. Results: Forty-seven patients were identified, and 5 were re-transplanted. Sixty-eight percent were male. The median age at diagnosis was 0.6 years, and for HSCT was 1.4 years. The most common diseases were chronic granulomatous disease (38%) followed by severe combined immune deficiencies (19%) and hemophagocytic lymphohistiocytosis (15%). Cord blood donors were the most used source of HSCT (44%). T cell-replete grafts from haploidentical donors using post-transplantation cyclophosphamide represent 37% of the cohort. All patients received conditioning, 62% with a non-myeloablative regimen. Calcineurin inhibitors were the main graft-versus-host disease prophylaxis (63.8%). Acute graft-versus-host disease developed in 35% of the total patients. The most frequent post-transplant infections were viral and fungal infections. The 1-year overall survival rates for the patients who received HSCT from identical, haploidentical, and cord sources were 80%, 72%, and 63%, respectively. The 5-year overall survival was 63%. Conclusions: HSCT is a curative treatment option for some IEI and can be performed with any donor type. Early and timely treatment in referral centers can improve survival. Mención de responsabilidad : Manuela Olaya, Alexis Franco, Mauricio Chaparro, Marcela Estupiñan, David Aristizabal, Natalia Builes-Restrepo, José L Franco, Andrés F Zea-Vera, Mayra Estacio, Eliana Manzi, Estefania Beltran, Paola Perez, Jaime Patiño, Harry Pachajoa & Diego Medina-Valencia Referencia : J Clin Immunol. 2020 Nov;40(8):1116-1123. DOI (Digital Object Identifier) : 10.1007/s10875-020-00856-w PMID : 32880086 En línea : https://link.springer.com/article/10.1007/s10875-020-00856-w Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5135 Hematopoietic stem cell transplantation in children with inborn errors of immunity: a multi-center experience in Colombia [documento electrónico] / Luz Natalia Builes Restrepo, . - 2020.
Obra : Journal of Clinical Immunology
Idioma : Inglés (eng)
Palabras clave : Hematopoietic stem cell transplantation child haploidentical transplantations pediatrics primary immunodeficiency diseases transplant recipients Resumen : Purpose: To characterize the pediatric population with inborn errors of immunity (IEI) that was treated with hematopoietic stem cell transplantation (HSCT) in three reference centers in Colombia. What have been the characteristics and outcomes of hematopoietic stem cell transplantation in pediatric patients with inborn errors of immunity in three reference care centers in Colombia between 2007 and 2018. Methods: We conducted an observational, retrospective cohort study in children with a diagnosis of IEI who underwent HSCT between 2007 and 2018. Results: Forty-seven patients were identified, and 5 were re-transplanted. Sixty-eight percent were male. The median age at diagnosis was 0.6 years, and for HSCT was 1.4 years. The most common diseases were chronic granulomatous disease (38%) followed by severe combined immune deficiencies (19%) and hemophagocytic lymphohistiocytosis (15%). Cord blood donors were the most used source of HSCT (44%). T cell-replete grafts from haploidentical donors using post-transplantation cyclophosphamide represent 37% of the cohort. All patients received conditioning, 62% with a non-myeloablative regimen. Calcineurin inhibitors were the main graft-versus-host disease prophylaxis (63.8%). Acute graft-versus-host disease developed in 35% of the total patients. The most frequent post-transplant infections were viral and fungal infections. The 1-year overall survival rates for the patients who received HSCT from identical, haploidentical, and cord sources were 80%, 72%, and 63%, respectively. The 5-year overall survival was 63%. Conclusions: HSCT is a curative treatment option for some IEI and can be performed with any donor type. Early and timely treatment in referral centers can improve survival. Mención de responsabilidad : Manuela Olaya, Alexis Franco, Mauricio Chaparro, Marcela Estupiñan, David Aristizabal, Natalia Builes-Restrepo, José L Franco, Andrés F Zea-Vera, Mayra Estacio, Eliana Manzi, Estefania Beltran, Paola Perez, Jaime Patiño, Harry Pachajoa & Diego Medina-Valencia Referencia : J Clin Immunol. 2020 Nov;40(8):1116-1123. DOI (Digital Object Identifier) : 10.1007/s10875-020-00856-w PMID : 32880086 En línea : https://link.springer.com/article/10.1007/s10875-020-00856-w Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5135 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001395 AC-2020-072 Archivo digital Producción Científica Artículos científicos Disponible
Título : New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, Fecha de publicación : 2020 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5105 New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT [documento electrónico] / Luz Natalia Builes Restrepo, . - 2020.
Obra : Blood Advances
Idioma : Inglés (eng)
Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5105 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001335 AC-2020-039 Archivo digital Producción Científica Artículos científicos Disponible Permalink
